EXPRESS MAIL LABEL NUMBER: EM5516176120

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Attorney Docket No.: 2813-L

Stewart D. Lyman and M. Patricia Beckmann

Group Art No. Unknown

Serial No.:

-to be assigned-

Examiner: Unknown

Filed:

December 19, 1997

For:

MEDIUM CONTAINING FLT3 LIGAND FOR CULTURING

HEMATOPOIETIC CELLS

INFORMATION DISCLOSURE STATEMENT

BOX SEQUENCE Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

Dear Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97(a) and 1.98, and in addition to the documents already listed on the Information Disclosure Statement in the priority applications, applicants hereby provide the documents listed on the attached Form PTO-1449.

- 1) U.S. Patent No. 5,199,942, Gillis
- 2) U.S. Patent No. 5,326,558, Turner et al.
- 3) U.S. Patent No. 5,192,553, Boyse et al.
- 4) EP 627487, Lyman et al.
- 5) Stewart et al., *Blood*, <u>81</u>:2283 (1993)

In addition, applicant wishes to bring the attention of the examiner to the following copending applications:

- 1) USSN 08/738,628, which discloses and claims an extracorporeal cell culture composition comprising flt3-ligand plus thrombopoietin.
- 2) USSN 08/399,404 which discloses and claims extracorporeal cell culture and transplantation kits, comprising flt3-ligand.
- 3) USSN 08/444,625 which discloses and claims a method for conducting autologous transplantation in a patient receiving cytoreductive therapy, comprising, *inter alia*,

expanding collected hematopoietic or stem cells with flt3-ligand; and methods of treating various conditions.

Since the submission of the documents listed on the Form PTO-1449 is made before the mailing of the first Office Action in connection with the above-captioned application, no fee under 37 C.F.R. 1.17(p) is believed to be required. However, should it be determined that a fee is necessary, Applicants authorize the Commissioner to charge Applicants' deposit account no 09-0089 in an amount necessary to permit consideration of this Information Disclosure Statement.

Respectfully submitted,

Attorney for Applicants Reg. No. 32,655

Immunex Corporation 51 University Street Seattle, WA 98101

Telephone: (206) 587-0430

CERTIFICATE OF MAILING

I hereby certify that the enclosed correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date listed below, and is addressed to BOX SEQUENCE, Hon. Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Date:

Signad

Camilla C Edwards